Introduction: In this study, we report on the development of an effective delivery system for siRNAs; a novel cell-penetrating peptide (CPP), T9(dR), obtained from transportan (TP), was used for in vivo and in vitro testing.
Methods: In this study, toxicity of T9(dR) and TP and efficient delivery of siRNA were tested in 293T, MDCK, RAW, and A549 cells. Furthermore, T9(dR)- and TP-delivered siRNAs against nucleoprotein (NP) gene segment of influenza virus (siNP) were studied in both cell lines and mice.
Results: Gel retardation showed that T9(dR) effectively condensed siRNA into nanoparticles sized between 350 and 550 nm when the mole ratio of T9(dR) to siRNA was ≥4:1. In vitro studies demonstrated that T9(dR) successfully delivered siRNA with low cellular toxicity into several cell lines. It was also observed that T9(dR)-delivered siRNAs inhibited replication of influenza virus more efficiently as compared to that delivered by TP into the MDCK and A549 cells. It was also noticed that when given a combined tail vein injection of siNP and T9(dR) or TP, all mice in the 50 nmol siNP group infected with PR8 influenza virus survived and showed weight recovery at 2 weeks post-infection.
Conclusion: This study indicates that T9(dR) is a promising siRNA delivery tool with potential application for nucleotide drug delivery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454991 | PMC |
| http://dx.doi.org/10.2147/DDDT.S195481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Original article: Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-center, randomized, double-blind, placebo-controlled phase 2 clinical trial.
Clin Microbiol Infect
January 2025
National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Department of Respiratory Medicine, Capital Medical University, Institute of Respiratory Medicine of Capital Medical University; Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. Electronic address:
Objectives: To evaluate the therapeutic effect of suraxavir marboxil (GP681, abbreviated as suraxavir) in adults with uncomplicated influenza.
Methods: We conducted a multi-center randomized, double-blind, placebo-controlled phase 2 trial in 18 Chinese centers. Participants had to be aged 18-65 years with positive influenza test, presenting with at least one influenza systemic and respiratory symptoms in at least moderate severity within 48 hours of onset.
State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens.
Semin Respir Crit Care Med
January 2025
Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
In this review, we present the efforts made so far in developing effective solutions to prevent infections caused by seven major respiratory pathogens: influenza virus, respiratory syncytial virus (RSV), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), , (), , and . Advancements driven by the recent coronavirus disease 2019 (COVID-19) crisis have largely focused on viruses, but effective prophylactic solutions for bacterial pathogens are also needed, especially in light of the antimicrobial resistance (AMR) phenomenon. Here, we discuss various innovative key technologies that can help address this critical need, such as (a) the development of Lung-on-Chip ex vivo models to gain a better understanding of the pathogenesis process and the host-microbe interactions; (b) a more thorough investigation of the mechanisms behind mucosal immunity as the first line of defense against pathogens; (c) the identification of correlates of protection (CoPs) which, in conjunction with the Reverse Vaccinology 2.
View Article and Find Full Text PDFUltrasensitive point-of-care multiplex diagnosis for influenza virus based robust quantum dot microsphere-lateral flow immunoassay.
Biosens Bioelectron
January 2025
Key Lab for Special Functional Materials of Ministry of Education, and School of Nanoscience and Materials Engineering, Henan University, 475004, Kaifeng, China. Electronic address:
Influenza A virus (IAV) and influenza B virus (IBV) with similar symptoms of infection caused a serious disease burden and economic losses in annual epidemic season, so it is important to quickly and accurately detect and distinguish between IAV and IBV during influenza season. Herein, the quantum dot microspheres (QDMS) were synthesized and applied to lateral flow immunoassays (LFIA), and a point-of-care (POC) biosensor that can discriminately and simultaneously diagnose IAV and IBV within 10 min was established. A double-sandwich QDMS nanotags was synthesized by immobilizing hydrophobic quantum dots (QDs) with chemical bonding method on a silica sphere template with an outer silica shell protection showed excellent stability and high fluorescence.
View Article and Find Full Text PDFThe WHO Disease Outbreak News during the Covid-19 pandemic.
PLOS Glob Public Health
January 2025
Center for Global Health Science and Security, Georgetown University Medical Center, Washington, DC, United States of America.
During the Covid-19 pandemic, the World Health Organization (WHO) was an important public source of information - not only about the pandemic, but also thousands of other potential health emergencies. Here, we examine the 242 reports published in the WHO Disease Outbreak News (DON) during the first four years of the Covid-19 pandemic (2020 to 2023), and document the diseases and regions that were reported. We find that multinational epidemics of diseases like Ebola virus and MERS-CoV continue to dominate the DON.
View Article and Find Full Text PDFRespiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine.
Pulmonology
December 2025
Portuguese Society of Pulmonology (SPP), Lisbon, Portugal.
Background: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract infection, hospitalisation and death in adults.
Methods: Based on evidence regarding the impact of RSV on adult populations at risk for severe infection and the efficacy and safety of RSV vaccines, the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine endorses this position paper with recommendations to prevent RSV-associated disease and its complications in adults through vaccination.
Conclusion: The RSV vaccine is recommended for people aged ≥50 years with risk factors (chronic obstructive pulmonary disease, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, chronic liver disease, immunocompromise, frailty, dementia, and residence in a nursing home) and all persons aged ≥60 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!